🩸 Increased RBC count and Hematocrit → Testosterone
💥Testosterone therapy stimulates erythropoiesis in the bone marrow, leading to increased red blood cell production and hematocrit levels.
💥This is why men receiving testosterone therapy are at risk for polycythemia, which can increase blood viscosity and thrombotic risk.
💥This effect is not typically associated with estrogen therapy.
🧬 Increased risk of Endometrial Cancer → Estrogen
💥Estrogen replacement therapy (ERT), when given without progesterone in women with an intact uterus, stimulates the endometrial lining.
💥Prolonged, unopposed estrogen exposure can cause endometrial hyperplasia, increasing the risk for endometrial carcinoma.
💥This adverse effect is unique to estrogen use and not linked to testosterone therapy.
🩹 Thrombosis (Blood Clots) → Both
💥Estrogen therapy increases liver production of clotting factors, raising the risk for deep vein thrombosis (DVT) and pulmonary embolism (PE).
💥Testosterone therapy can also increase clot risk indirectly through polycythemia and blood viscosity, though less pronounced than estrogen.
💥Thus, thromboembolic events are a shared risk of both therapies.
💉 Hypertension → Both
💥Both estrogen and testosterone can contribute to increased blood pressure.
💥Estrogen can cause fluid retention and alter the renin-angiotensin system, while testosterone increases sodium and water retention through its effects on the kidneys.
💥Therefore, hypertension is considered a possible adverse effect of both hormone therapies.